| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
ML228 (ML-228; CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) which potently activate HIF in vitro as well as its downstream target VEGF. Hypoxia and ischemia are related to numerous public health problems affecting most major organ systems. Examples include the cardiovascular, pulmonary, renal, neurologic, and musculoskeletal systems. Furthermore, angiogenesis is required for tissue repair and regeneration. In cases of ischemia, whether due to injury or disease, enhancing blood supply is a common goal. The most significant pathway for cellular response to hypoxia is the hypoxia inducible factor (HIF) pathway. HIFs are transcription factors responsible for the activation of genes which encode proteins that mediate adaptive responses to reduced oxygen availability. The molecular probe ML228 demonstrated activity in a cell-based HIF-mediated gene reporter assay with an EC50 around 1 μM. This probe did not inhibit the proteasome, activated HIF stabilization and nuclear translocation, and induced expression of a HIF specific downstream gene (VEGF). It had no apparent toxicity below 30 μM and appeared to be an iron chelator.
| Targets |
The research community is using ML228 (CID-46742353) as a new chemotype to investigate HIF activation and its possible therapeutic applications. In addition to having a highly different structure from well-known HIF activators, ML228 is devoid of the nearly universally present acidic functional groups seen in PHD inhibitors, which could be crucial for the treatment of specific diseases [1][2].
|
|---|---|
| ln Vitro |
The research community is using ML228 (CID-46742353) as a new chemotype to investigate HIF activation and its possible therapeutic applications. In addition to having a highly different structure from well-known HIF activators, ML228 is devoid of the nearly universally present acidic functional groups seen in PHD inhibitors, which could be crucial for the treatment of specific diseases [1][2].
ML228 was a top active compound in three HIF-specific activity assays: a hypoxia response element (HRE)-luciferase reporter assay (EC50 = 1.23 μM), a high-content imaging assay for HIF-1α nuclear translocation (EC50 = 1.40 μM), and a real-time PCR assay for VEGF transcription induction (EC50 = 1.63 μM). It was inactive in a proteasome inhibition counterscreen assay, indicating its effects are not due to general proteasome inhibition. [1] To investigate the potential role of metal chelation in its mechanism, the effect of excess iron or zinc on ML228's activity in the HRE-luciferase assay was tested. Adding 50 μM iron to the media caused a dramatic rightward shift in the dose-response curve (EC50 shifted from 1.12 μM to 15.6 μM) and substantially decreased the magnitude of response. Adding 50 μM zinc produced a smaller rightward shift (EC50 = 5.01 μM). This suggests ML228 can chelate iron, which is consistent with some known mechanisms of HIF activation. A cell toxicity assay ruled out that the reduced activity with added metals was due to cell death. [1] ML228 was submitted to a radioligand binding assay panel of 68 GPCRs, ion channels, kinases, and transporters at 10 μM. It inhibited >75% of radioligand binding at six targets: human adenosine A3 receptor (80% inhibition), human dopamine transporter (DAT) (87%), human opiate μ receptor (85%), human potassium channel hERG (86%), human serotonin 5-HT2B receptor (92%), and rat sodium channel site 2 (105% inhibition). Moderate binding inhibition (50-75%) was observed at ten additional targets. [1] |
| ln Vivo |
Following spinal cord injury (SCI), treatment with ML228 (injection; 1 µg/kg; 7 days) can enhance the local hypoxic-ischemic environment, lessen subsequent SCI damage, and encourage neurological recovery [3].
In a rat model of spinal cord injury (SCI), treatment with ML228 (1 µg/kg) significantly improved functional recovery compared to the untreated control group, as assessed by the Basso, Beattie, and Bresnahan (BBB) locomotor rating scale at 3 and 7 days post-operation. [3] Western blot analysis of injured spinal cord tissue showed that the expression levels of both HIF-1α and VEGF proteins were significantly higher in the ML228-treated group compared to the untreated control group at 1, 3, and 7 days after surgery. [3] Immunohistochemistry analysis of spinal cord sections confirmed that the expression and positive staining of both HIF-1α and VEGF were stronger and more prevalent in the ML228-treated group compared to the untreated control group at all time points examined (1, 3, and 7 days post-injury). [3] Hematoxylin and eosin (H&E) staining of spinal cord tissue 7 days post-operation showed that, compared to the untreated control group, the tissue structure in the ML228-treated group was more ordered and clear, with fewer necrotic areas and glial scars observed. [3] |
| Cell Assay |
A high-throughput cell-based HIF-mediated gene reporter screen was conducted using a stably transfected human U2OS osteosarcoma cell line expressing luciferase under the control of hypoxia response elements (HREs). Compounds were initially screened at 7.5 μM, and hits were further characterized with full dose-response curves. Positive control desferrioxamine (DFO, 100 μM) had an EC50 of 17.8 μM in this assay. [1]
A high-content imaging assay was used to examine the accumulation and nuclear translocation of HIF-1α in U2OS cells expressing HIF-1α fused to Green Fluorescent Protein (GFP). This assay provided a secondary confirmation of HIF pathway activation. [1] A real-time PCR assay was performed to evaluate the ability of compounds to induce transcription of VEGF, a downstream target gene of the HIF pathway. [1] A commercially available cell-based proteasome inhibition assay was used as a counterscreen to eliminate compounds acting as general proteasome inhibitors. ML228 was inactive in this assay. [1] A cell toxicity assay (CellTiter-Glo®) was performed in the same U2OS cell line to rule out that the observed changes in HIF activity, particularly in the presence of added metals, were due to compound-induced cell death. No toxicity was observed under the tested conditions. [1] |
| Animal Protocol |
Animal/Disease Models: SD rats [3]
Doses: 1 µg/kg Route of Administration: injection; 7-day Experimental Results: Central nervous system SCI was diminished and related symptoms were relieved. A total of 90 twelve-week-old female Sprague Dawley rats (weight 220-255 g) were used. [3] The rats were randomly divided into three groups (n=30 each): a sham group (operation without spinal cord injury), a control group (spinal cord injury without treatment), and a treatment group (spinal cord injury receiving ML228 treatment). [3] The treatment group received ML228 at a dose of 1 µg/kg. The specific route and frequency of administration are not described in detail within the provided text. [3] Spinal cord injury was induced via hemisection at the T10 level under anesthesia. Sham-operated rats underwent the same procedure but without cord transection. [3] Behavioral testing (BBB scoring) was performed prior to operation and at 1, 3, and 7 days post-operation. Animals were sacrificed at these time points for tissue collection and analysis. [3] |
| References |
|
| Additional Infomation |
ML228 belongs to the 1,2,4-triazine class of compounds, with the 3, 5, and 6 positions of the triazine ring substituted with pyridin-2-yl, ([biphenyl]-4-ylmethyl)amino, and methyl groups, respectively. It is an activator of the hypoxia-inducible factor (HIF) pathway. It belongs to the biphenyl, 1,2,4-triazine, secondary amine, and pyridine classes of compounds. ML228 represents a novel chemical type for studying HIF activation, with a structure that differs from known PHD inhibitors because it lacks acidic functional groups (e.g., carboxylic acids) commonly found in such inhibitors. This characteristic may be advantageous for certain applications, such as potential central nervous system targets that require crossing the blood-brain barrier. [1]
Based on the significant reduction in HRE-luciferase activity in the presence of excess iron, its mechanism of action is speculated to involve iron chelation. [1] Molecular modeling (using SurflexSim for shape-based similarity scoring) suggests that the binding pattern of ML228 to PHD2 is less likely to be similar to that of published PHD inhibitors. Based on the low shape similarity score (5.5 out of 10), and the manual docking results indicated negative steric hindrance at the PHD2 active site. This suggests that its HIF activation mechanism may differ from classic competitive PHD inhibition. [1] ML228 has been recommended as a molecular probe tool compound for researchers to study HIF pathway activation and its therapeutic potential. [1] |
| Molecular Formula |
C₂₇H₂₁N₅
|
|
|---|---|---|
| Molecular Weight |
415.49
|
|
| Exact Mass |
415.179
|
|
| CAS # |
1357171-62-0
|
|
| Related CAS # |
|
|
| PubChem CID |
46742353
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
686.0±65.0 °C at 760 mmHg
|
|
| Flash Point |
368.7±34.3 °C
|
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
|
| Index of Refraction |
1.671
|
|
| LogP |
5.05
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
32
|
|
| Complexity |
536
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
QNRODODTMXCRKU-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32)
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4068 mL | 12.0340 mL | 24.0680 mL | |
| 5 mM | 0.4814 mL | 2.4068 mL | 4.8136 mL | |
| 10 mM | 0.2407 mL | 1.2034 mL | 2.4068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Complete response curves forML228.Bioorg Med Chem Lett.2012 Jan 1;22(1):76-81. |
Effects of metals on HRE luciferase activity ofML228.Bioorg Med Chem Lett.2012 Jan 1;22(1):76-81. |
Shape based molecular graphics aligned with the SurflexSim conformational ensemble illustrate the large dissimilarity in shape and volume ofML228(green surface) with the composite shape of the published PHD2 ligands. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
